9+1AI

Our AI reveals hidden risk and enables earlier clinical action with any electrocardiogram.

health AImedtechdigital health

Visit website LinkedIn ↗

Stageunfunded

Raised$0

Founded2023

Employees3

LocationCharlotte, NC

About

9+1AI is a digital health company pioneering FDA Breakthrough-designated artificial intelligence diagnostics for cardiovascular care. Our flagship innovation uses advanced ECG-AI for earlier detection of heart failure and unlocking new opportunities for preventive care. Spun out of the University of Tennessee Research Foundation and Wake Forest School of Medicine, we are building the HeartSight Library—an expanding portfolio of AI algorithms designed to detect and monitor over 18 cardiovascular and systemic conditions from a simple ECG. Our vision is to reimagine the ECG as a universal diagnostic platform—bringing biomarker-level precision to clinical, telehealth, and wearable environments worldwide.

Product

Value proposition: Deploy clinically validated AI to unlock hidden insights in every electrocardiogram and transform patient care.
Target customers: health systems, hospitals, clinics, telehealth providers, consumer health platforms
Regulatory: FDA Breakthrough Device Designation for ECG AI Diagnostics

Founders

John Jefferies — Founder / CEO
Oguz Akbilgic — Chief Science Officer

Products

ECG AI diagnosticsrisk stratification for subclinical cardiovascular riskintegration-ready AI analytics for ECGs

Key features

Identify subclinical cardiovascular risk in normal ECGsClinically validated at scale (10M ECGs)Real-time insight across care and consumer workflowsPHI-secure, HIPAA-compliantRESTful API integrationsGuides targeted follow-up (echocardiograms, labs)

Technologies

machine learning / AIECG signal processingreal-time analyticsRESTful APIs

Integrations

healthcare deviceshealth systemstelehealth platformsconsumer technologies

Target conditions

cardiovascular riskECG-based diagnoses

Care settings

hospitalclinictelehealthhome health

Certifications

FDA Breakthrough Device Designation

Awards

FDA Breakthrough Device Designation

Traction metrics

more than 10 million electrocardiograms used in validation

News

Five Innovative Healthcare Startups Selected for Inaugural gBETA ... · 2026-04-06T00:00:00.000Z
Commercial Expansion and AI Pipeline Put Algorae Pharmaceuticals (ASX: 1AI) Back in the Spotlight · 2026-07-01T02:56:00.000Z
Algorae (1AI) Clarifies NSW Health Supply Contract · 2026-07-02T00:02:51.000Z
Algorae Pharmaceuticals launches AI-powered platform to generate novel drug candidates · 2024-09-25T19:24:55.000Z
Algorae Pharmaceuticals joins Sovereign AI Infrastructure initiative as healthcare and life sciences launch partner · 2026-06-30T18:51:04.000Z
1AI:ASX Announcement - $3 million Debt Facility Secured with ScotPac - 21 Jan 2026 · 2026-01-21T23:09:44.000Z

Browse similar startups

Related startups

Blueprint Nutrition & Fitness — Charlotte, NC
Carolina Behavioral Health — Burlington, NC
CollectiveGood Health — Chapel Hill, NC
DiabesityMD — Raleigh, NC
FemHealth Insights — Cary, NC
First Patient Engagement Center — Charlotte, NC
9xmed — Mission, TX
Aayur Solutions LLC — Sheridan, WY
Absolute Med-Solutions
Abstract Digiops LLC — Dover, DE
Abxtract — San Francisco, CA
Acaderma — San Francisco, CA

Profile updated Jul 29, 2026. Sources: 9plus1.ai, linkedin.com